Related Experiment Videos

[Impact of overweight on clinical outcomes in patients undergoing coronary revascularization]

Jun-ping Kang1, Chang-sheng Ma, Qiang Lü

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Insights

Patients with heart failure undergoing coronary revascularization who are overweight or obese have a similar or better prognosis than normal-weight patients. This finding suggests that higher body mass index (BMI) does not worsen outcomes in this population.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Clinical Outcomes

Context:

  • Heart failure (HF) is a complex condition often associated with comorbidities.
  • Coronary revascularization is a key treatment for coronary artery disease (CAD) in HF patients.
  • The impact of body mass index (BMI) on outcomes after revascularization in HF patients remains an area of investigation.

Purpose:

  • To investigate the association between body mass index (BMI) and clinical outcomes in patients with heart failure who underwent coronary revascularization.
  • To compare the risks of total mortality, cardiac mortality, and major adverse cardiovascular and cerebrovascular events (MACCE) across different BMI categories.

Summary:

  • A single-center registry analyzed 1010 heart failure patients who underwent coronary revascularization, categorized by BMI (normal, overweight, obese).
  • Overweight and obese patients presented with more comorbidities, including hypertension and higher triglyceride levels.
  • Multivariate analysis revealed that obese patients had a significantly decreased hazard risk for total mortality and MACCE compared to normal BMI patients.

Impact:

  • The findings suggest that obesity or overweight in heart failure patients with coronary heart disease does not lead to worse prognosis after revascularization.
  • This study contributes to understanding the 'obesity paradox' in cardiovascular disease.
  • Results may inform clinical management and risk stratification strategies for heart failure patients undergoing revascularization.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...